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ABSTRACT
Human epidermal growth factor receptor 2 (HER2) pro-
teins are overexpressed in a high proportion of gastric
cancer (GC) cases and affect the maintenance of cancer
stem cell (CSC) subpopulations, which are used as tar-
gets for the clinical treatment of patients with HER2-
positive GC. Despite improvements in survival, numer-
ous HER2-positive patients fail treatment with trastuzu-
mab, highlighting the need formore effective therapies. In
this study, we generated a novel type of genetically
modiﬁed human T cells, expressing a chimeric antigen
receptor (CAR), and targeting the GC cell antigen HER2,
whichharbors theCD137andCD3ζmoieties.Ourﬁndings
show that the expanded CAR-T cells, expressing an
increased central memory phenotype, were activated by
the speciﬁc recognition of HER2 antigens in an MHC-in-
dependent manner, and effectively killed patient-derived
HER2-positive GC cells. In HER2-positive xenograft
tumors, CAR-T cells exhibited considerably enhanced
tumor inhibition ability, long-term survival, and homing to
targets, compared with those of non-transduced T cells.
The sphere-forming ability and in vivo tumorigenicity of
patient-derived gastric cancer stem-like cells, expressing
HER2 and the CD44 protein, were also inhibited. Our
results support the future development and clinical
application of this adoptive immunotherapy in patients
with HER2-positive advanced GC.
KEYWORDS chimeric antigen receptor, HER2, gastric
cancer, cancer stem cell, CD137, immunotherapy
INTRODUCTION
Gastric cancer (GC) is one of the most common malignant
cancers worldwide, especially in China. GC-associated
morbidity and mortality, estimated by the National Central
Cancer Registry of China (NCCR), ranks second among
cancers, and resulted in approximately 679 thousand deaths
and 498 thousand new cases in 2015 (Chen et al., 2016).
Despite improvements in GC therapy, many patients fail
treatment because of tumor recurrence and metastasis. As
the predominant treatment for advanced gastric cancer
(AGC), chemotherapy is inefﬁcient and toxic because of its
nonspeciﬁc antitumor activity. Even among patients treated
with ﬁrst-line chemotherapy, the overall response rate (ORR)
is less than 50%, and the median overall survival (mOS) is
only 6.6 to 18.4 months (Ter Veer et al., 2016). Thus, we
focused on adoptive cellular immunotherapy (ACI), which
involves the use of genetically engineered T lymphocyte or
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NK cell treatments for hematological malignancies (Porter
et al., 2011).
Chimeric antigen receptor (CAR) T-cell immunotherapy is
an ACI in which the CAR-redirected T cells, expressing
engineered receptors speciﬁc to a particular antigen, are
reintroduced into patients and elicit an effective antitumor
immune response. CAR-T cells have been in development
for 2 decades, beginning with ﬁrst-generation chimeric
genes composed of single-chain variable fragments (scFvs)
of monoclonal antibody (mAb) and FcR γ chains or TCR/
CD3 ζ chains (Eshhar et al., 1993). Second- and third-gen-
eration, with one or more costimulatory molecules, such as
CD28, CD137 (4-1BB), ICOS, and OX40, have since been
developed. CD19-targeted CAR-T cells display high antitu-
mor activity in children and adults with B-cell malignancies
(Park et al., 2016). Additionally, a series of CARs, targeting
different antigens, have been constructed and validated in
clinical trials. Although this strategy has been effective and
presents advantages, such as high speciﬁcity and MHC-in-
dependent effects, its potential clinical application in solid
tumors is hampered by concerns over its safety and efﬁcacy.
Studies on the use of CAR-T cells in the treatment of GC
are lacking, mainly because of the high heterogeneity of GC
cells. Positive clinical outcomes, obtained using the targeted
agent trastuzumab, suggest that the surface antigen HER2
may serve as a target for CAR-T cell therapy. HER2, also
known as CD340 or Neu, is a member of the EGFR family,
and is encoded by the ERBB2 proto-oncogene. ERBB2 is
faintly expressed in the luminal and glandular epithelium
under normal conditions and is overexpressed in carcinomas
of the breast, ovary, endometrium, lung, pancreas, bladder,
and stomach (Thibault et al., 2013). Positive rates of HER2
ampliﬁcation, and overexpression in GC patients, are distinct
and range from 10% to 27%, and 8.2% to 53.4%, respec-
tively; this is likely due to differences in methodologies,
ethnic groups, pathological types, and tumor locations
among the affected patients (Vakiani, 2015). Additionally,
ERBB2 ampliﬁcation contributes to the maintenance of stem
cell (GCSC) subpopulations of gastric cancer (Jiang et al.,
2012); the expression status of ERBB2 is related to disease
progression and poor prognosis (Van Cutsem et al., 2016).
In this study, we designed novel, lentivirus-mediated, CAR
harboring, anti-HER2 scFv, CD3ζ and CD137 signaling
domains and evaluated the antitumor activity of CAR-modi-
ﬁed T cells against primary GC cells and GCSCs in vitro and
in vivo. Our results support future clinical trials testing the
use of this CAR-modiﬁed T-cell immunotherapy in patients
with AGC and multi-drug resistance.
RESULTS
Identiﬁcation and characterization of novel HER2-
targeted CAR-T cells
A second-generation CAR, consisting of an HER2-speciﬁc
scFv linked to a hinge domain, a transmembrane (TM)
domain, and CD137ζ and CD3ζ moieties in sequence
(Fig. 1A), was constructed and inserted into a pseudotyped,
clinical-grade lentiviral vector system. A green ﬂuorescence
protein (GFP) was added to CAR.HER2-CD137ζ to verify
transfection efﬁciency; CAR-CD137ζ-GFP, without an scFv,
was constructed to serve as control.
Tcells were originally generated from the peripheral blood
mononuclear cells (PBMCs) of three healthy donors. Len-
tivirus-mediated CAR gene transfection was performed on
day 2 of PBMC culture in vitro. The total numbers of CAR-
transduced, mock-transduced, and non-transduced (NT)
cells were expanded on an average of 85, 75, and 90 times,
respectively, on day 12 of culture (Fig. 1B). Using ﬂuores-
cence-activated cell sorting (FACS) analysis on day 12, we
determined that the CAR group mainly comprised a large
population of CD8+CD56− cells (72.55% ± 7.26%) and a
small fraction of cells expressing the indicated central
memory T (Tcm) phenotypes (CD45RO+CD62L+CCR7+,
23.35% ± 7.59%). The Tcm population was signiﬁcantly
larger than the corresponding population in the NT group
(Figs. 1C and S1). Mean transfection efﬁciencies of 34.22%
± 4.00% and 32.95% ± 4.76% were veriﬁed in the ﬁnal
CART-HER2 and mock T-cell populations, respectively
(Figs. 1D and S2). Groups of cells, exhibiting optimal growth,
were selected from one of the three abovementioned
donors, to undergo subsequent functional assays.
CART-HER2 cells speciﬁcally kill HER2+ GC cell lines
and primary GC cells ex vivo
FACS was used to assess the surface expression of HER2
proteins in a series of human GC cell lines (GCCLs),
including the N87, 7901, AGS, HGC27, MGC803, BGC823,
and MKN45 cells, and in primary gastric cancer cells
(PGCCs) obtained from two patients with GC. HER2 was
strongly expressed in all the GCCLs, with percentages
ranging from 84.39% to 98.60%. In contrast, the PGCCs
from patient 1 (PGCC 1) exhibited a percentage of 56.80%,
and the PGCCs from patient 2 (PGCC 2) exhibited a per-
centage of 2.48% (Fig. 2A). Therefore, two different GCCLs
(N87 and 7901), and two patient-derived cell lines, were
selected for further study. HER2 knockdown (HER2KD) was
performed in N87 and 7901 cells via transduction of a len-
tivirus-mediated short hairpin RNA-HER2 (shRNA-HER2)
(Fig. 2B). Transduction of the GFP gene was performed for
isolation and tracking. HER2KD tumor cells served as control
cells.
To verify the speciﬁc activity of CART-HER2 cells against
HER2+ tumor cells, we incubated T cells with tumor cells at
an effector-to-target (E/T) ratio of 20:1 for 4 h. After the
incubation, the levels of cytokines released by CART-HER2
cells, including IL-2, IFN-γ, IL-4, GM-CSF, TNF-α, and
Granzyme B (GZMB), were signiﬁcantly elevated in the
supernatants of HER2high+ N87 and 7901 cells compared
with those of mock Tcells and NT Tcells (Fig. 2C). However,
RESEARCH ARTICLE Yanjing Song et al.









substantially lower cytokine levels were detected when
CART-HER2 cells were co-cultured with HER2KD N87 and
7901 cells than when CART-HER2 cells were co-cultured
with HER2high+ N87 and 7901 cells (Fig. 2C). Similarly, the
speciﬁc activity of CART-HER2 cells against patient-derived
GC cells was veriﬁed by incubating the T cells with PGCC 1.
Furthermore, minimal levels of cytokines were detected
when effector T cells interacted with HER2− PGCC 2
(Fig. 2D). These results indicate that CART-HER2 cells can
speciﬁcally recognize GC cells with high and low expression
of HER2, and can then be activated at varying levels by GC
cells.
Next, to evaluate the cytotoxicity of CART-HER2 cells
against GC cells, we performed time- and dose-dependent
lactate dehydrogenase (LDH) release assays. As shown in
Fig. 3A and 3B, CART-HER2 cells, evaluated using the 4-h
LDH assay, and incubated at a ratio of 20:1 E/T, exhibited
higher average killing activity against HER2high+ N87 cells
(65.3% ± 5.0%), 7901 cells (81.5% ± 2.5%), and PGCC 1
(53.6% ± 4.2%) than did mock and NT T cells having a low
rate of lysis. Moreover, the cytotoxicity of CART-HER2 cells
was increased as the E/T ratio increased (Fig. 3A). Similarly,
the 8-h LDH assay showed that the average killing activity,
exhibited by CART-HER2 cells against HER2+ GC cells
when incubated at a ratio of 20:1 E/T, was higher than that
exhibited by mock or NT T cells (Fig. 3C), but was not
signiﬁcantly higher than that exhibited by CART-HER2 cells
in the 4-h assay (Fig. 3D). In the control group of target cells,
the average killing activity levels, exhibited by CART-HER2
cells against HER2KD N87 and 7901 cells during the 4-h
LDH assay when incubated at a ratio of 20:1 E/T, were
33.6% ± 3.0% and 45.3% ± 2.2%, respectively; these levels
were still signiﬁcantly higher than those exhibited by mock or
NT T cells (Fig. 3B). There was no signiﬁcant difference
among the three types of effector T cells with respect to
cytotoxicity against HER2− PGCC 2 (Fig. 3A). Hence, we
demonstrated that CART-HER2 cells possess potent cyto-
toxic activity against HER2+ GC cells.
CART-HER2 cells exhibit effective and persistent
antitumor activity against xenografts derived
from HER2+ GCCLs in mice
The subcutaneous xenotransplanted tumor model of
HER2high+ 7901 cells was established in BALB/c nude mice
to determine the antitumor ability of CART-HER2 cells
in vivo. Treatment with effector cells was performed on day
12, when the mean tumor volume (TV) had reached
approximately 100 mm3 after subaxillary inoculation with
tumor cells. Tumor growth was measured twice weekly until
the maximum tumor diameter was greater than 2 cm or until
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Figure 1. Generation, expansion, and characterization of HER2-directed chimeric antigen receptor T cells. (A) Schematic
representation of anti-HER2 CAR gene sequence (not drawn to scale). (B) Average expansion (-fold) of CART-HER2, mock T, and
NT T cells, produced using PBMCs from three healthy donors; the cells were cultured in vitro for 10–14 days. Mean and SDs are
shown for three different T-cell lines. (C) Phenotypic features of CART-HER2 and NT T cells, from three healthy donors, were
evaluated by FACS analysis on day 12 of culture. Mean positive rates ± SD from three different T-cell lines are shown.
(D) Transfection efﬁciency of CAR or mock gene into Tcells was determined by FACS analysis using the marker GFP on day 12. The
data are represented as means ± SD. *Represents P < 0.05.
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Figure 2. Speciﬁc activity of HER2-directed chimeric antigen receptor T cells against HER2+ GC cells. (A) FACS was used to
test the surface expression of HER2 proteins in a series of human GC cell lines, including N87, 7901, AGS, HGC27, MGC803,
BGC823, MKN45, and primary GC cells from two patients with GC. (B) HER2 expression in N87 and 7901 cells was downregulated
via transduction of lentivirus-mediated short hairpin RNA-HER2. The knockdown effects of HER2 expression in sorted GFP-positive
cells were evaluated by FACS analysis. (C) The levels of cytokines, released by CART-HER2, mock T, and NT T cells, were
measured by enzyme-linked immunosorbent assay (ELISA) after 4-h incubation with HER2high+ and HER2KD GC cells at an effector-
to-target (E/T) ratio of 20:1. (D) The levels of cytokines, released by CART-HER2 and NT T cells, were measured by ELISA after 4-h
incubation with patient-derived GC cells at an E/T ratio of 20:1. The data are represented as the mean cytokine concentrations ± SD
(pg/mL) from triplicate cultures. NS represents no statistical signiﬁcance, *represents P < 0.05, **represents P < 0.01.
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over 90 days. As shown in Figs. 4A and S3, in the HER2high+
mouse model, the rates of tumor growth were considerably
inhibited by treatment with CART-HER2 cells, while tumors
in the control group continued to grow rapidly after the
injection with NT T cells. The mean TV and mean tumor
weight (TW) in the CART-HER2 group were 654 ± 247 mm3
(P < 0.01) and 426 ± 138 mg (P < 0.01), respectively, while
those in the NT group reached 1,769 ± 462 mm3 and 1,050 ±
306 mg, respectively, on day 32. Finally, the signiﬁcantly
improved survival (77 ± 11 days), exhibited by the remaining
HER2high+ tumor-bearing mice (n = 3) treated with CART-
HER2 cells, indicated the speciﬁc antitumor activity of CART-
HER2 cells.
To determine the persistence of the CART-HER2 cells, we
used qPCR at serial time points to measure the copy num-
bers of CAR in the peripheral blood of mice in the experi-
mental group. The copy numbers of CAR remained at a
detectable level for at least 56 days in the blood of the
remaining three mice and were positively correlated with the
improved survival of HER2high+ mice (Fig. 4B).
To assess the homing ability of CART-HER2 cells,
transgene copy number detection, as well as hematoxylin-
eosin (HE) staining, and immunohistochemical (IHC) label-
ing, were performed on tumor samples from sacriﬁced mice.
The results showed high levels of DNA copy numbers
(Fig. 4C) and considerable increases in the recruitment of
human CD3+ Tcells in the experimental group, whereas only
a small number of CD3+ T cells were observed in the NT
group (Fig. 4D). These ﬁndings strongly suggest that CART-
HER2 cells can effectively trafﬁc to target sites.
CART-HER2 cells effectively respond to GCSCs
To verify whether CART-HER2 cells can inhibit the growth of
CSC subpopulations in primary GC, suspended cell spheres,
which are aggregations of CSCs, were generated in serum-
free media containing growth factors. The mean number of
spheres per well, in an ultra-low adherent 6-well plate, was
32 on day 20 after inoculation with HER2+ PGCCs from
patient 1. The rates of the surface expression of HER2, and
the GCSCs-speciﬁc marker CD44, in separated spheres
were 73.5% and 98.6%, respectively, as determined by
FACS analysis (Fig. 5A). Then, a co-culture of tumor spheres
with 2 × 105 CART-HER2 cells or NT T cells per well, was
grown in an ultra-low adherent 24-well plate using serum-
free media. CART-HER2 cells migrated to the tumor spheres
by chemotaxis after 6 h of co-culture, resulting in the
phagocytosis and degradation of the tumor spheres by the
CART-HER2 cells. The numbers of spheres in ﬁve wells fell
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Figure 3. Speciﬁc cytotoxicity exhibited by HER2-directed chimeric antigen receptor T cells against HER2+ GC cell line and
primary GC cells ex vivo. (A) The cytotoxic activity of CART-HER2, mock T, and NT Tcells against HER2high+ and HER2KD GC cells
was determined using a 4-h lactate dehydrogenase (LDH) release assay in a dose-dependent manner. HER2− primary GC cells were
used as controls. (B) A 4-h LDH release assay, at an effector-to-target (E/T) ratio of 20:1, was used to compare cytotoxicity between
CART-HER2, mock T, and NT T cells against different GC cells (C) An 8-h LDH release assay, at an E/T ratio of 20:1, was used to
compare cytotoxicity between CART-HER2, mock T, and NT Tcells against different GC cells. (D) Cytotoxicity comparisons of CART-
HER2 cells against different GC cells were performed between the 4-h and 8-h LDH release assays at an E/T ratio of 20:1. All of the
results are expressed as the mean of triplicate values ± SD. NS represents no statistical signiﬁcance, **represents P < 0.01.
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CART-HER group were disintegrated into small pieces after
48 h, indicating that the CART-HER2 cells were signiﬁcantly
more effective than the NT T cells at targeting the tumor
spheres (Fig. 5B). The tumorigenicity of the CSCs in the
BALB/c nude mice was also remarkably restrained by
intravenous treatment with CART-HER2 cells. The average
TV and TW in the CART-HER2 group were 450 ± 106 mm3
and 310 ± 81 mg, respectively, while those in the NT group
were 1,377 ± 196 mm3 and 852 ± 124 mg, respectively, on
day 63 (Figs. 5C and S4).
DISCUSSION
To the best of our knowledge, this study is the ﬁrst to conﬁrm
that CART-HER2 cells show speciﬁc, effective, and persis-
tent tumor-killing activity against HER2-positive primary GC
cells and GCSCs in pre-clinical tests. We designed an anti-
HER2 scFv and CD137-containing CAR, which was trans-
duced into T cells by a clinical-grade lentiviral vector system.
Our results show that the cytotoxicity, exhibited by CART-
HER2 cells against HER2-positive GC cells and HER2-
knockdown cells, was signiﬁcantly higher than that exhibited
by NT Tcells; this rules out the inﬂuence of the vector system
on our results and suggests that CAR-T cells contacted the
target cells with high afﬁnity and lysed them in an MHC-
independent manner. The secretion levels of multiple
cytokines were positively correlated with the antitumor
effects of CAR-T cells. The cytokines that were upregulated
included the pro-inﬂammatory factors IFN-γ, IL-2, IL-4, GM-
CSF, and TNF-α, which are crucial for T-cell activation,
proliferation, and differentiation. These cytokines are also
implicated in the occurrence of severe cytokine release
syndrome (CRS) (Teachey et al., 2016). HER2-positive
tumor growth in mice was markedly inhibited by intravenous
infusion of CAR-T cells. We detected persistently high copy
numbers of CAR in the blood and high numbers of inﬁltrating
CD3+ cells in tumors, all of which indicated the persistence,
homing, and antitumor activity of CAR-T cells. The sphere-
forming ability, and in vivo tumorigenicity, of primary GCSCs
were signiﬁcantly suppressed by treatment with CAR-T cells;
thus, we conclude that CART-HER2 cells can mount an
effective response to CSCs.
Components of the HER2 signaling pathway have been
used extensively as a key immunotherapy target in therapy
against various solid tumors. Although several anti-HER2














































































































Figure 4. Antitumor efﬁcacy of HER2-directed chimeric antigen receptor T cells against xenografts derived from HER2+ GC
cell lines in mice. (A) Two million HER2high+ 7901 cells were injected subcutaneously into the unilateral axillary region of BALB/c
nude mice on day 0. Five HER2high+ tumor-bearing mice per group were randomly assigned to the CART-HER2 and NT groups
before treatment. When the mean tumor volume reached approximately 100 mm3 on day 12, intravenous treatment with T cells was
performed. Mice with maximum tumor diameters over 2 cm were sacriﬁced on day 33. The tumor volume data are represented as
mean ± SD (mm3). The tumor weight data are represented as mean ± SD (mg). Images of tumor samples from sacriﬁced mice are
shown. (B) The persistence of the infused CART-HER2 cells in the peripheral blood. qPCR was performed at serial time points, after
infusion with CART-HER2 cells, to determine the expression levels of CAR in the peripheral blood of mice (n = 8). (C) Correlations of
CAR copy numbers in tumor tissue and blood samples, obtained after the HER2high+ mice, treated with CART-HER2 cells, were
sacriﬁced on day 33. (D) Hematoxylin-eosin (HE) and immunohistochemical (IHC) staining for anti-CD3 were performed on tumor
samples from sacriﬁced mice.
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TDM-1, have been tested in clinical GC trials, only trastu-
zumab is currently approved for the ﬁrst-line treatment of
AGC (Fanotto et al., 2016). Hence, to enhance treatment
efﬁcacy and minimize drug resistance, the HER2-directed
CAR approach has been developed and validated in diverse
tumor-bearing mouse models, including those of osteosar-
coma (Rainusso et al., 2012), breast cancer (Sun et al.,
2014), renal cancer (Schonfeld et al., 2015), and glioblas-
toma (Zhang et al., 2016). Recently, the ﬁrst clinical study to
use HER2-speciﬁc CAR-T cells in patients with HER2-posi-
tive sarcoma showed that the HER2-directed CAR approach
performed well with respect to safety and efﬁcacy (ORR,
7/17) (Ahmed et al., 2015). These data suggest that HER2
may be a suitable target for our CAR-modiﬁed T-cell
immunotherapy. In this study, we demonstrated that CART-
HER2 cells have high afﬁnity for all types of GC cells, even
those expressing low levels of HER2, and display an
effective and persistent killing activity in HER2-positive
tumor-bearing mice.
Additional costimulatory domains, incorporated into CARs,
are indispensable for engineering T cells that show a potent
and sustained antitumor activity (Dai et al., 2016). Despite the
existence of multiple alternative costimulatory molecules, the
majority of modular designs, used in clinical trials, are based
on theCD137andCD28signaling domains. Tcells expressing
CD137-containingCARsare likely to showhigher proliferation
and persistence than those expressing CD28-containing
CARs (Zhang et al., 2015). The mechanism underlying these
functional differences remains unclear. One study showed
that theearly exhaustion of Tcells, inducedat varying levels by
an antigen-independent tonic signaling caused by CAR clus-
tering, was ameliorated by CD137 domains. This may have
occurred via inhibition of the expression of exhaustion-related






































































Figure 5. Effective response by CART-HER2 cells to GCSCs. (A) FACS analysis was used to determine the surface expression of
HER2 and CD44 proteins in gastric cancer stem cells from suspended tumor spheres. (B) Co-culture of tumor spheres with 2 × 105
CART-HER2 cells, or NT Tcells, per well was performed in an ultra-low adherent 24-well plate using serum-free media. Images of the
killing activity, exerted by CART-HER2 cells against tumor spheres at serial time points, are shown. (C) Ten thousand gastric cancer
stem cells were injected subcutaneously into the unilateral axillary region of BALB/c nude mice on day 0. Five mice per group were
randomized to the CART-HER2 and NT groups. When the mean tumor volume reached approximately 100 mm3 on day 42,
intravenous treatment with T cells was performed. Mice with maximum tumor diameters over 2 cm were sacriﬁced on day 63. The
tumor volume data are represented as mean ± SD (mm3). The tumor weight data are represented as mean ± SD (mg). Images of
tumor samples from sacriﬁced mice are shown.
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metabolism, apoptosis, and responsiveness to hypoxia (Long
et al., 2015). Similarly, another study showed the pivotal role of
CD137 signaling-induced metabolic reprogramming in the
enhanced persistence of CAR-T cells. These metabolic
changes, including the considerable enhancements in respi-
ratory capacity, fatty acid oxidation, and mitochondrial bio-
genesis, result in the differentiation of central memory and
prolonged survival of CAR-T cells (Kawalekar et al., 2016).
The results of these studies agree with our ﬁndings of
increased proportions of CD45RO+CD62L+CCR7+ cells, and
long-term survival of CAR-T cells, in vivo. However, CD28
CARs exert greater cytotoxic effects on Tcells than do CD137
CARs. Combining these two domains, or their ligands, results
in higher antitumor efﬁcacy in some mouse models (Zhao
et al., 2015); however, this structural design warrants further
clinical study.
Transduction of CAR into primary T cells is accomplished
using a series of gene transfer platforms, ranging from a
plasmid vector- to virus-mediated gene delivery; each
approach offers its pros and cons with respective efﬁciency,
toxicity, practicability, and cost. The recombinant plasmid was
initially used for the genetic modiﬁcation of Tcells because of
safety concerns; although thismethod is associatedwith a low
risk of transgene-speciﬁc immune responses and insertional
mutagenesis, it delivers low transfection efﬁciency and limited
cell survival (Jensen et al., 2000). Another approach, not
involving transgene integration, is the mRNA electroporation
system, which exhibits very high transfection efﬁciency and
facilitates rapid, but transient,CAR expression in Tcells (Zhao
et al., 2006). Recently, the Sleeping Beauty (SB) and Pig-
gyBac (PB) transposon/transposase systems, which can
integrate genes into target cellular genomes, were evaluated
in CAR-related therapies. The low efﬁciency of genetic
transposition is a major obstacle preventing the broad clinical
application of this method; however, the low cost, convenient
manufacturing, and mild toxicity of this system render it
attractive as an alternative treatment strategy (Kebriaei et al.,
2016). Surprisingly, one study demonstrated a markedly
enhancedCAR transduction using aminicircle vector carrying
an SB system (Monjezi et al., 2017). Because they are cur-
rently the most widely used vectors, retroviral and lentiviral
vectors allow for the stable and efﬁcient transfection of CAR
into T cells. The ability of these modiﬁed cells to elicit a well-
tolerated, effective, and persistent therapeutic response has
beenproven in patientswith different types of cancer (Jackson
et al., 2016).
Tumors possess a hierarchical structure, in which CSCs
serve as the tumor-initiating cells and are responsible for
drug resistance, tumor progression, recurrence, and
metastasis; thus eradication of CSCs is a promising method
for treating cancer (Pan et al., 2015). GCSCs have also been
identiﬁed using speciﬁc markers, such as CD44 (Takaishi
et al., 2009); the stemness properties of GCSCs are studied
using two standard approaches: the in vitro sphere-forming
assay and in vivo serial tumor passaging (Brungs et al.,
2016). Some studies have found that HER2 plays a critical
role in maintaining the CSC subpopulation of GC cells (Jiang
et al., 2012), as well as that of other tumor cells, such as
breast tumor cells (Korkaya and Wicha, 2013). Therefore,
because of the eradication of CSCs, HER2-targeted therapy
may result in improved treatment outcomes in patients with
HER2-positive GC. In this study, we used sphere cultures
in vitro, and tumor formation in mice, to successfully
validate the self-renewal and tumor-initiating capacity of
CD44+HER2+ GCSCs from primary gastric tumors. We
found that CART-HER2 cells efﬁciently phagocytized and
degraded the tumor spheres and suppressed the growth of
xenograft tumors in nude mice inoculated with GCSCs.
These results show that CART-HER2 cells exerted potent
cytotoxic effects on GCSCs and suggest that CAR-T cells
are potentially effective in preventing the recurrence and
metastasis of GC. However, the practical impact of this
treatment needs to be veriﬁed further in future clinical trials,
given the genetic and functional heterogeneity of CSCs
(Kreso and Dick, 2014) and the complexity of the tumor
microenvironment (Plaks et al., 2015).
Although the therapeutic effects of CAR-T cells on
hematological malignancies, especially CAR-T cells target-
ing CD-19, have been elucidated, the development of CARs
for the treatment of solid tumors has been hindered by the
paucity of optimal antigens, the inability of T cells to migrate
to and inﬁltrate primary lesions, transgene immunogenicity
and toxicity, ongoing evolution of cancer cells, possible
existence of CSC populations, and the immunosuppressive
tumor microenvironment. Therefore, additional methods for
implementing CAR-T cell therapy against solid tumors have
been explored. Modifying T cells with inducible cytokine or
chemokine receptor transgenes has been shown to enhance
their antitumor activity and ability to localize. For example,
supplementary secretion of IL-12 by T cells, engineered with
CAR and CAR-inducible Il-12 genes in targeted sites,
improved the intrinsic functions of these T cells and boosted
the local immune response by facilitating the recruitment and
activation of other killing cells, the initiation of innate immu-
nity, and modulation of suppressor cells (Chmielewski et al.,
2014). Similarly, synchronous blockade of PD-1 in CAR-T
cells, via genetic modiﬁcation, also prolonged cell survival
(Cherkassky et al., 2016) and augmented tumor-killing efﬁ-
cacy in mouse tumor models (Liu et al., 2016). Another
approach involves designing more intelligent CAR con-
structions to minimize the off-target effects. These con-
structions include bispeciﬁc CAR-T cells, which can be
activated only by the identiﬁcation of both CAR molecules
(Wilkie et al., 2012), and the synNotch circuit, in which Tcells
are armed only by a synthetic Notch receptor activated by
one target to induce the expression of a CAR against
another target (Roybal et al., 2016). Additionally, combining
CAR-T cells with ibrutinib in patients with leukemia (Fraietta
et al., 2016) may represent a potential strategy for enhancing
therapeutic efﬁcacy against solid tumors.
In conclusion, we showed that HER2-directed CAR-T
cells exhibit effective and persistent antitumor activity
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against patient-derived GC cells, and GCSCs, in vitro and
in vivo. Our results suggest that these modiﬁed T cells may
be applicable in patients with HER2-positive GC; however,
the toxicity and immunogenicity of CAR need to be addres-
sed in future clinical trials.
MATERIALS AND METHODS
Cells
The human GCCLs, N87, 7901, AGS, HGC27, MGC803, BGC823,
and MKN45 were obtained from the Institute of Basic Medicine of
Chinese PLA General Hospital (PLAGH). PGCCs were obtained
from the Department of General Surgery of PLAGH. All GC cells
were cultured in RPMI-1640 medium supplemented with 10% fetal
bovine serum (FBS), except the MGC803 cells, which were cultured
in DMEM (high glucose) containing 10% FBS.
Isolation of primary gastric tumor cells
Fresh human GC tissues were obtained from patients immediately
after resection. All samples were transported on ice to the laboratory
within 30 min, and were immediately mechanically disaggregated
into 1-mm pieces using scissors. These tumor pieces were then
digested with 1 mg/mL collagenase I and 1 mg/mL collagenase IV
(Life Technologies, Waltham, MA, USA), and diluted in phosphate
buffered saline (PBS) at 37°C for at least 1 h. Digestion was termi-
nated with DMEM/F12 containing 20% FBS (Life Technologies).
Tumorsphere culture and formation
To form spheres, digested cells from primary gastric tumors were
cultured at a density of 104 cells per well in ultra-low attachment
6-well plates (Corning, NY, USA) in DMEM/F12 supplemented with
2% B27 (Invitrogen, CA, USA), EGF (20 ng/mL, Invitrogen), bFGF
(10 ng/mL, Invitrogen), LIF (10 ng/mL, Peprotech, Hartford, CT,
USA), and HEPES (Invitrogen). The culture medium was replen-
ished twice per week. Spheres with a diameter >100 µm were
counted 14 days after being seeded.
Constructs and lentiviral packaging
The scFv nucleotide sequence, targeting HER2 antigens, was
derived from our proprietary product (patent CN105384824A,
China). The entire DNA sequence of CAR.HER2-CD137ζ, which
contained anti-HER2 scFv, human CD8a hinge, and CD137ζ and
CD3ζ signaling domains, was constructed based on our previously
published CAR sequence (Dai et al., 2015). Complete clinical-grade
viral particles were produced using transfection package cells with a
four-plasmid system. The GFP-harboring vector CAR.HER2-
CD137ζ-GFP was also constructed to verify transduction efﬁciency.
Generation and expansion of CART-HER2 cells
Anticoagulated fresh blood was obtained from three healthy donors.
PBMCs in buffy coats were puriﬁed using lymphocyte separation
medium (Cedarlane), via density gradient centrifugation, after the
serum was collected from the blood samples. The washed PBMCs
were directly added to the lymphocyte culture medium (Takara)
supplemented with the anti-CD3 mAb OKT3 (500 ng/μL) and IL-2
(300 U/mL). The generation and expansion of CAR-T cells was per-
formed in accordance with our published protocol pertaining to cyto-
kine-induced killer (CIK) cells (Wang et al., 2013). Stable transfection
of Tcells with lentivirus-mediated CARwas conducted on day 2 of cell
culturing. Transfection efﬁciency and phenotypic properties of the
CAR-Tcells were evaluated by FACS analysis on day 12.
HER2 knockdown by lentivirus-mediated shRNA
Knockdown of HER2 expression in N87 and 7901 cells was per-
formed by transfection with a lentivirus harboring human HER2-
speciﬁc shRNA and the GFP gene. The lentivirus was purchased
from GenePharma. The target sequence for HER2 was 5′-
GGAAGGACATCTTCCACAAGA-3′. HER2 knockdown was con-
ﬁrmed by qPCR and FACS analysis.
Flow cytometry analysis and cell sorting
All of the anti-human antibodies used in this study, including HER2
(phycoerythrin, PE), CD3 (chlorophyll protein complex PerCP), CD4
(ﬂuorescein isothiocyanate, FITC), CD8-PE, CD45RO (allophyco-
cyanin, APC), CD56-APC, CD62L-PE, CCR7-PE-Cy7, and CD44-
PE-Cy7, were purchased from BD Biosciences. Isotype-matched
control mAbs were applied in all the procedures. Additionally, GFP-
positive HER2KD N87 and 7901 cells were separated from
untransfected cells, based on the degree of ﬂuorescence, by a BD
Inﬂux cell sorter (BD Biosciences). FACS data were analyzed by a
FACSCalibur ﬂow cytometer (BD Biosciences) and FlowJo software
(Version 10.0.7, FlowJo, Ashland, OR).
Cytotoxicity assays
The speciﬁc in vitro antitumor activity of CART-HER2 cells was eval-
uated using a standard LDH release assay (Promega). Brieﬂy, the
different typesof target cellswere seeded in triplicate 96-well plates, at
a density of 104 cells per well, with 50 μL of medium; then, an equal
volume of effector cells, or control medium, was added to each well to
ensure an E/T ratio of 20:1, 10:1, 5:1, or 1:1. After 4-h and 8-h co-
incubation, cell supernatants were obtained by centrifugation. Fifty
microliters of sample from each well was transferred to new plates to
measure the absorbance signals usinga plate reader (MultiskanMK3,
ThermoScientiﬁc); the remaining sampleswere collected for cytokine
measurements. The average cytotoxicity percentage was calculated
according to the formula provided by Promega.
Cytokine secretion assays
The harvested samples of supernatant, obtained from the 4-h co-
incubation of effector cells with target cells at an E/T ratio of 20:1,
were assessed for the levels of cytokine secretion. The concentra-
tions of IL-2, IL-4, TNF-α, IFN-γ, GM-CSF, and GZMB were batch-
measured using an enzyme-linked immunosorbent assay kit (BD
Biosciences) in accordance with the operating manual.
Quantitative real-time PCR
To determine the levels of CAR.HER2-CD137ζ gene expression,
real-time PCR was performed using an ABI PRISM 7900HT
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Sequence Detection System (Applied Biosystems) according to a
procedure published previously (Till et al., 2012). A 153-base pair
(bp) DNA sequence, harboring fragments of the CD8a and CD137ζ
moieties, was ampliﬁed using the following primers: 5′-GGTCCT
TCTCCTGTCACTGGTT-3′ and 5′-TCTTCTTCTTCTGGAAATCGG
CAG-3′. The transcription level of HER2 in HER2KD N87 and 7901
cells was quantiﬁed via ampliﬁcation of an 86-bp fragment using the
following primers: 5′- ATATATCGAGGCGATAGGGTTAAGG-3′ and
5′-CCGGGGCATATCTTCTGGAAT-3′. β-Actin was used as a control
for normalization.
Xenograft mouse model of GC
The animal experiments were approved by the Animal Ethics Com-
mittee of PLAGH. BALB/c nudemicewere purchased from the Beijing
Vital River Laboratory Animal Technology Co. Four- to 5-week-old
female BALB/c nude mice were bred under speciﬁc pathogen-free
conditions in the Laboratory Animal Center of PLAGH. One hundred
microliters of 2 × 106 HER2high+ 7901 cells was injected subcuta-
neously into the unilateral axillary region of BALB/c nude mice on
day 0. The rate of xenotransplanted tumor formation was 100%. At
least ﬁve HER2high+ tumor-bearing mice were randomly assigned to
the CART-HER2 and NT groups before treatment. The TV of
each mouse was measured twice weekly using a vernier caliper, and
was calculated according to the following formula: TV = 1/2 ×
length × width2. On day 12, when the mean TV reached approxi-
mately 100 mm3, 200 μL of 2 × 107 CART-HER2 cells, or NT T cells,
were infused into the caudal veins of the mice. For the detection of
CAR copy number, peripheral blood samples were collected from the
caudal veins, or eyeballs, of HER2high+ mice, treated with CART-
HER2 cells, every 15 days. Inoculation with GCSCs and treatment in
BALB/c nude mice were performed as described above. The total
number of injected CSCs was 1 × 104, and the tumor formation rate
was 100%. Five mice per group were randomized to the CART-HER2
and NT groups. Mice with maximum tumor diameters over 2 cm, or
20% loss of body weight, were euthanized.
Histological and immunohistochemical examinations
Tumor tissue samples, which had been resected from sacriﬁced
mice, were ﬁxed in 4% paraformaldehyde for 4–6 h, dehydrated in
ethyl alcohol, and embedded in parafﬁn, before being cut into mul-
tiple 6-μm thin sections using a microtome. HE and IHC staining
were performed using standard procedures. Primary rabbit anti-hu-
man CD3 antibody (ab5690, Abcam) and a secondary biotinylated
goat anti-rabbit antibody were used for IHC staining.
Statistical analysis
All results are reported as the mean ± standard deviation (SD), and
were analyzed by the unpaired t-test. Data were plotted using
GraphPad Prism software version 6.0c for Mac OS. P-values < 0.05
were considered statistically signiﬁcant.
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